Patents by Inventor Noel Marie-France THOMSEN

Noel Marie-France THOMSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazolopyridine derivatives and uses thereof
    Patent number: 11787785
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: October 17, 2023
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Alysia Dales, Janetta Dewhurst, Matthew James Hesse, Rama Jain, John Ryan Kerrigan, Hasnain Ahmed Malik, James R. Manning, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela Y F Ting
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20230279394
    Abstract: The present invention is directed to compositions and methods for the treatment of hemoglobinopathies.
    Type: Application
    Filed: December 16, 2020
    Publication date: September 7, 2023
    Inventors: Muluken BELEW, Simone BONAZZI, James BRADNER, Artiom CERNIJENKO, Jennifer Stroka COBB, Natalie DALES, John Ryan KERRIGAN, Philip LAM, Hasnain Ahmed MALIK, Carsten RUSS, Frederic SIGOILLOT, Susan C. STEVENSON, Noel Marie-France THOMSEN, Pamela TING
  • Pyrazolopyridine Derivatives and Uses thereof
    Publication number: 20230108325
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: March 14, 2022
    Publication date: April 6, 2023
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Alysia Dales, Janetta Dewhurst, Matthew James Hesse, Rama Jain, John Ryan Kerrigan, Hasnain Ahmed Malik, James R. Manning, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela YF TING
  • 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20230067476
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.
    Type: Application
    Filed: November 8, 2021
    Publication date: March 2, 2023
    Inventors: Claire ADCOCK, Simone BONAZZI, Artiom CERNIJENKO, Philip LAM, Kathryn Taylor LINKENS, Hasnain Ahmed MALIK, Noel Marie-France THOMSEN, Michael Scott VISSER
  • 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 11566022
    Abstract: The present disclosure relates to compounds of formula (I?) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders, including hemoglobinopathies, sickle cell disease and beta-thalassemia.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: January 31, 2023
    Assignee: NOVARTIS AG
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Natalie Dales, John Ryan Kerrigan, Philip Lam, Hasnain Ahmed Malik, Gary O'Brien, Andrew W. Patterson, Noel Marie-France Thomsen, Pamela Ting
  • 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof
    Publication number: 20230019617
    Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: June 1, 2022
    Publication date: January 19, 2023
    Inventors: Simone Bonazzi, Artiom Cernijenko, Jennifer Stroka Cobb, Janetta Dewhurst, John Ryan Kerrigan, Gary O'Brien, MooJe Sung, Noel Marie-France Thomsen, Pamela Ting
  • 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof
    Publication number: 20220402904
    Abstract: The present disclosure relates to compounds of formula (I?) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
    Type: Application
    Filed: December 16, 2020
    Publication date: December 22, 2022
    Inventors: Simone BONAZZI, Artiom CERNIJENKO, Jennifer Stroka COBB, Natalie DALES, John Ryan KERRIGAN, Philip LAM, Hasnain Ahmed MALIK, Gary O'BRIEN, Andrew W. PATTERSON, Noel Marie-France THOMSEN, Pamela TING
  • SUBSTITUTED 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20220144798
    Abstract: The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, Rx, X1, X2, X3, n, n1, and q are as defined herein, and methods of making and using same.
    Type: Application
    Filed: February 13, 2020
    Publication date: May 12, 2022
    Inventors: Rohan Eric John BECKWITH, Simone BONAZZI, Artiom CERNIJENKO, Philip LAM, Noel Marie-France THOMSEN
  • 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
    Patent number: 11192877
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: December 7, 2021
    Assignee: Novartis AG
    Inventors: Claire Adcock, Simone Bonazzi, Artiom Cernijenko, Philip Lam, Kathryn Taylor Linkens, Hasnain Ahmed Malik, Noel Marie-France Thomsen, Michael Scott Visser
  • 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
    Publication number: 20200017461
    Abstract: The present disclosure provides a compound of Formula (I?): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.
    Type: Application
    Filed: July 8, 2019
    Publication date: January 16, 2020
    Inventors: Claire ADCOCK, Simone BONAZZI, Artiom CERNIJENKO, Philip LAM, Kathryn Taylor LINKENS, Hasnain Ahmed MALIK, Noel Marie-France THOMSEN, Michael Scott VISSER
  • Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
    Patent number: 10058534
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Grant
    Filed: February 17, 2018
    Date of Patent: August 28, 2018
    Assignee: Novartis AG
    Inventors: Heather Elizabeth Burks, Michael A. Dechantsreiter, Guo He, Jill Nunez, Stefan Peukert, Clayton Springer, Yingchuan Sun, Noel Marie-France Thomsen, George Scott Tria, Bing Yu
  • BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20180169063
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Application
    Filed: February 17, 2018
    Publication date: June 21, 2018
    Inventors: Heather Elizabeth BURKS, Michael A. DECHANTSREITER, Guo HE, Jill NUNEZ, Stefan PEUKERT, Clayton SPRINGER, Yingchuan SUN, Noel Marie-France THOMSEN, George Scott TRIA, Bing YU
  • Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
    Patent number: 9931317
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: April 3, 2018
    Assignee: Novartis AG
    Inventors: Heather Elizabeth Burks, Michael A. Dechantsreiter, Guo He, Jill Nunez, Stefan Peukert, Clayton Springer, Yingchuan Sun, Noel Marie-France Thomsen, George Scott Tria, Bing Yu
  • BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20170112805
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Application
    Filed: January 5, 2017
    Publication date: April 27, 2017
    Inventors: Heather Elizabeth BURKS, Michael A. DECHANTSREITER, Guo HE, Jill NUNEZ, Stefan PEUKERT, Clayton SPRINGER, Yingchuan SUN, Noel Marie-France THOMSEN, George Scott TRIA, Bing YU
  • Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
    Patent number: 9561211
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: February 7, 2017
    Assignee: Novartis AG
    Inventors: Heather Elizabeth Burks, Michael A. Dechantsreiter, Guo He, Jill Nunez, Stefan Peukert, Clayton Springer, Yingchuan Sun, Noel Marie-France Thomsen, George Scott Tria, Bing Yu
  • BENZOTHIOPHENE DERIVATIVES AND COMPOSITIONS THEREOF AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20160184265
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Application
    Filed: March 10, 2016
    Publication date: June 30, 2016
    Applicant: NOVARTIS AG
    Inventors: Heather Elizabeth BURKS, Michael A. DECHANTSREITER, Guo HE, Jill NUNEZ, Stefan PEUKERT, Clayton SPRINGER, Yingchuan SUN, Noel Marie-France THOMSEN, George Scott TRIA, Bing YU
  • Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
    Patent number: 9321746
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: April 26, 2016
    Assignee: NOVARTIS AG
    Inventors: Heather Elizabeth Burks, Michael A. Dechantsreiter, Guo He, Jill Nunez, Stefan Peukert, Clayton Springer, Yingchuan Sun, Noel Marie-France Thomsen, George Scott Tria, Bing Yu
  • Compounds and compositions as selective estrogen receptor degraders
    Patent number: 8877801
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: November 4, 2014
    Assignee: Novartis AG
    Inventors: Heather Elizabeth Burks, Michael A. Dechantsreiter, Guo He, Jill Nunez, Stefan Peukert, Clayton Springer, Yingchuan Sun, Noel Marie-France Thomsen, George Scott Tria, Bing Yu
  • COMPOUNDS AND COMPOSITIONS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20140235660
    Abstract: The present invention relates to compounds of formula I: in which n, m, X, Y1, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention; capable of being both potent antagonists and degraders of estrogen receptors. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with aberrant estrogen receptor activity.
    Type: Application
    Filed: February 12, 2014
    Publication date: August 21, 2014
    Applicant: NOVARTIS AG
    Inventors: Heather Elizabeth BURKS, Michael A. DECHANTSREITER, Guo HE, Jill NUNEZ, Stefan PEUKERT, Clayton SPRINGER, Yingchuan SUN, Noel Marie-France THOMSEN, George Scott TRIA, Bing YU